Cushing Syndrome Clinical Presentation
- Author: Gail K Adler, MD, PhD; Chief Editor: George T Griffing, MD more...
History
- Patients with Cushing syndrome may complain of weight gain, especially in the face, supraclavicular region, upper back, and torso.
- Frequently, patients notice changes in their skin, including purple stretch marks, easy bruising, and other signs of skin thinning.
- Because of progressive proximal muscle weakness, patients may have difficulty climbing stairs, getting out of a low chair, and raising their arms.
- Menstrual irregularities, amenorrhea, infertility, and decreased libido may occur in women due to inhibition of pulsatile secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which likely is due to interruption of luteinizing hormone-releasing hormone (LHRH) pulse generation.
- In men, inhibition of LHRH and FSH/LH function may lead to decreased libido and impotence.
- Psychological problems such as depression, cognitive dysfunction, and emotional lability may develop.
- New-onset or worsening of hypertension and diabetes mellitus, difficulty with wound healing, increased infections, osteopenia, and osteoporotic fractures may occur.
- Patients with an ACTH-producing pituitary tumor (Cushing disease) may develop headaches, polyuria and nocturia, visual problems, or galactorrhea.
- If sufficient mass effect from the tumor is present on the anterior pituitary, hyposomatotropism, hypothyroidism, hyperprolactinemia or hypoprolactinemia, and hypogonadism may develop.
- Rapid onset of symptoms of glucocorticoid excess in conjunction with virilization in women or feminization in men suggests an adrenal carcinoma as the underlying cause of the Cushing syndrome.
Physical
- Obesity
- Patients may have increased adipose tissue in the face (moon facies), upper back at the base of neck (buffalo hump), and above the clavicles (supraclavicular fat pads).
- Central obesity with increased adipose tissue in the mediastinum and peritoneum; increased waist-to-hip ratio greater than 1 in men and 0.8 in women; and, upon CT scan of the abdomen, increased visceral fat is evident.
- Skin
- Facial plethora may be present, especially over the cheeks.
- Violaceous striae, often wider than 0.5 cm, are observed most commonly over the abdomen, buttocks, lower back, upper thighs, upper arms, and breasts.
- Ecchymoses may be present.
- Patients may have telangiectasias and purpura.
- Cutaneous atrophy with exposure of subcutaneous vasculature tissue and tenting of skin may be evident.
- Glucocorticoid excess may cause increased lanugo facial hair.
- If glucocorticoid excess is accompanied by androgen excess, as occurs in adrenocortical carcinomas, hirsutism and male pattern balding may be present in women. Steroid acne, consisting of papular or pustular lesions over the face, chest, and back, may be present.
- Acanthosis nigricans, which is associated with insulin resistance and hyperinsulinism, may be present. The most common sites are axilla and areas of frequent rubbing, such as over elbows, around the neck, and under the breasts.
- Cardiovascular and renal[2]
- Hypertension and possibly edema may be present due to cortisol activation of the mineralocorticoid receptor leading to sodium and water retention.
- Gastroenterologic
- Peptic ulceration may occur with or without symptoms. Particularly at risk are patients given high doses of glucocorticoids (rare in endogenous hypercortisolism).
- Endocrine
- Galactorrhea may occur when anterior pituitary tumors compress the pituitary stalk, leading to elevated prolactin levels.
- Signs of hypothyroidism, such as slow reflex relaxation, may occur from an anterior pituitary tumor whose size interferes with proper thyroid-releasing hormone (TRH) and thyroid-stimulating hormone (TSH) function. Similarly, other pituitary function may be interrupted.
- Low testosterone levels in men may lead to decreased testicular volume from inhibition of LHRH and LH/FSH function.
- Skeletal/muscular
- Proximal muscle weakness may be evident.
- Osteoporosis may lead to incident fractures and kyphosis, height loss, and axial skeletal bone pain. Avascular necrosis of the hip is also possible from glucocorticoid excess.
- Neuropsychological
- Patients may experience emotional liability, fatigue, and depression.
- Visual-field defects, often bitemporal, and blurred vision may occur in individuals with large ACTH-producing pituitary tumors that impinge on the optic chiasma.
- Adrenal crisis
- Patients with cushingoid features may present to the emergency department in adrenal crisis. Adrenal crisis may occur in patients on steroids who stop taking their glucocorticoids or neglect to increase their steroids during an acute illness. It also may occur in patients who have recently undergone resection of an ACTH-producing or cortisol-producing tumor or who are taking adrenal steroid inhibitors.
- Physical findings that occur in a patient in adrenal crisis include hypotension, abdominal pain, vomiting, and mental confusion (secondary to low serum sodium or hypotension). Other findings include hypoglycemia, hyperkalemia, hyponatremia, and metabolic acidosis.
Causes
- Exogenous steroid administration
- Administration of exogenous steroids may lead to the development of Cushing syndrome.
- Symptoms of glucocorticoid excess generally occur with the administration of oral steroids; however, occasionally injections of steroids into joints and the use of steroid inhalers can cause Cushing syndrome.
- Patients with diseases that respond to steroid therapy are especially likely to receive steroids and thus develop Cushing syndrome. Such disorders include a wide variety of rheumatologic, pulmonary, neurological, and nephrologic diseases.
- Patients who have undergone organ transplants are also at risk for developing Cushing syndrome due to exogenous steroids required as part of graft antirejection medication regimens.
- Endogenous glucocorticoid overproduction
- ACTH-producing pituitary adenoma
- Pituitary adenomas that secrete ACTH are derived from corticotrophs in the anterior pituitary.
- ACTH secreted by corticotrophs is released into the circulation and acts on the adrenal cortex to produce hyperplasia and stimulate the secretion of adrenal steroids.
- These adenomas, if large, can result in loss of production of other anterior pituitary hormones (TSH, FSH, LH, growth hormone, and prolactin) and the posterior pituitary hormone vasopressin.
- Pituitary tumors can also compress the hypophyseal stalk leading to hyperprolactinemia from loss of dopamine inhibition.
- Nelson syndrome is caused by a large ACTH-secreting pituitary tumor; it is often locally invasive, difficult to cure, and associated with hyperpigmentation. In patients who undergo adrenalectomy without pituitary irradiation, the incidence of Nelson syndrome is about 20-25%.
- Large pituitary adenomas may press on the optic chiasm, causing visual-field deficiencies that often present as bitemporal field cuts.
- Primary adrenal lesions
- Overproduction of glucocorticoids may be due to an adrenal adenoma, adrenal carcinoma, or macronodular or micronodular adrenal hyperplasia. The zona fasciculata and zona reticularis layers of the adrenal cortex normally produce glucocorticoids and androgens. Glucocorticoid-secreting tumors are derived from these cells and, thus, may secrete both glucocorticoids and androgens.
- In general, excess androgen secretion is suggestive of an adrenal carcinoma rather than an adrenal adenoma. These glucocorticoid-producing tumors generally do not secrete aldosterone, which is produced in the zona glomerulosa layer of the adrenal cortex.
- The Carney complex is a familial form of micronodular hyperplasia of the adrenal gland. It is an autosomal dominant disorder and ACTH independent cause of Cushing syndrome. Pigmented skin lesions and mesenchymal and endocrine tumors characterize the disorder. Cushing syndrome may be overt, subclinical, cyclical, or periodic.
- McCune-Albright syndrome is a rare cause of precocious puberty. It is associated with hyperfunction of the adrenal glands that may lead to Cushing syndrome.[3]
- ACTH-producing pituitary adenoma
- Ectopic ACTH is sometimes secreted by oat cell or small-cell lung tumors or by carcinoid tumors.
Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab. Aug 2005;90(8):4955-62. [Medline].
Pereira AM, Delgado V, Romijn JA, et al. Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. Eur J Endocrinol. Feb 2010;162(2):331-40. [Medline].
Brown RJ, Kelly MH, Collins MT. Cushing Syndrome in the McCune-Albright Syndrome. J Clin Endocrinol Metab. Feb 15 2010;[Medline].
Flack MR, Oldfield EH, Cutler GB Jr, et al. Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome. Ann Intern Med. Feb 1 1992;116(3):211-7. [Medline].
Kidambi S, Raff H, Findling JW. Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. Eur J Endocrinol. Dec 2007;157(6):725-31. [Medline].
Tyrrell JB, Findling JW, Aron DC, Fitzgerald PA, Forsham PH. An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. Ann Intern Med. Feb 1986;104(2):180-6. [Medline].
Raff H. Utility of salivary cortisol measurements in Cushing's syndrome and adrenal insufficiency. J Clin Endocrinol Metab. Jul 14 2009;[Medline].
Carroll T, Raff H, Findling JW. Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis. Endocr Pract. Jul-Aug 2009;15(4):335-42. [Medline].
Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA. Mar 4 1992;267(9):1244-52. [Medline].
Mulligan GB, Eray E, Faiman C, et al. Reduction of false-negative results in inferior petrosal sinus sampling with simultaneous prolactin and corticotropin measurement. Endocr Pract. Jan-Feb 2011;17(1):33-40. [Medline].
Donadille B, Groussin L, Waintrop C, et al. Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center. J Clin Endocrinol Metab. Feb 2010;95(2):537-44. [Medline].
Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol. Nov 2007;157(5):561-9. [Medline].
Lila AR, Gopal RA, Acharya SV, George J, Sarathi V, Bandgar T, et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract. Nov-Dec 2010;16(6):968-76. [Medline].
Batista DL, Oldfield EH, Keil MF, et al. Postoperative testing to predict recurrent Cushing disease in children. J Clin Endocrinol Metab. Aug 2009;94(8):2757-65. [Medline].
Eddy RL, Jones AL, Gilliland PF, Ibarra JD Jr, Thompson JQ, MacMurry JF Jr. Cushing's syndrome: a prospective study of diagnostic methods. Am J Med. Nov 1973;55(5):621-30. [Medline].
Findling JW, Doppman JL. Biochemical and radiologic diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am. Sep 1994;23(3):511-37. [Medline].
Kaye TB, Crapo L. The Cushing syndrome: an update on diagnostic tests. Ann Intern Med. Mar 15 1990;112(6):434-44. [Medline].
Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev. Oct 1998;19(5):647-72. [Medline].
Nieman L, Cutler GB Jr. Cushing's syndrome. In: Degroot LJ, Besser M, Burger HG, et al, eds. Endocrinology. 3rd ed. Philadelphia, Pa: WB Saunders; 1995:1741-69.
Pavlatos FC, Smilo RP, Forsham PH. A rapid screening test for Cushing's syndrome. JAMA. Aug 30 1965;193:720-3. [Medline].
Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's syndrome. Am J Med. Nov 1952;13(5):597-614. [Medline].
Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med. Jun 17 2003;138(12):980-91. [Medline].
Yanovski JA, Cutler GB Jr. Glucocorticoid action and the clinical features of Cushing's syndrome. Endocrinol Metab Clin North Am. Sep 1994;23(3):487-509. [Medline].
Corcept Therapeutics Incorporated announces FDA approval of Korlym (mifepristone) 300 mg tablets: First and only approved medication for Cushing's Syndrome Patients. Corcept Therapeutics. Available at http://www.corcept.com/news_events/pr_1329524335. Accessed February 21, 2012.
| States of Increased HPA Activity | States of Decreased HPA Activity |
| Chronic stress[9] Melancholic depression Anorexia nervosa Obsessive-compulsive disorder Panic disorder Excessive exercise Chronic active alcoholism Alcohol and nicotine withdrawal Diabetes mellitus Central obesity Sexual abuse Hyperthyroidism Premenstrual tension syndrome Cushing syndrome Pregnancy | Adrenal insufficiency Atypical/seasonal depression Chronic fatigue syndrome Fibromyalgia Hypothyroidism Nicotine withdrawal Post glucocorticoid therapy Post-Cushing syndrome Postpartum period Post-chronic stress[9] Rheumatoid arthritis |
Print
